{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tiong IS"],"funding":["NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","Children with Cancer UK","Cancer Research UK","Medical Research Future Fund (MRFF)","Leukemia &amp; Lymphoma Society (LLS) Specialized Center of Research (SCOR) (Strasser)"],"pagination":["1026-1030"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8048658"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["192(6)"],"pubmed_abstract":["Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1<sup>mut</sup> measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CR<sub>MRD-</sub> ) without transplantation. Six of seven patients with molecular relapse/progression achieved CR<sub>MRD-</sub> after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1<sup>mut</sup> MRD."],"journal":["British journal of haematology"],"pubmed_title":["Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia."],"pmcid":["PMC8048658"],"funding_grant_id":["29806","15-194"],"pubmed_authors":["Ivey A","Cummings N","Russell NH","Potter NE","Taussig DC","Nguyen P","Teh TC","Tiong IS","Fong CY","Grigg AP","Latif AL","Raj K","Dillon R","Wei AH","Runglall M","Schwarer AP"],"additional_accession":[]},"is_claimable":false,"name":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.","description":"Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1<sup>mut</sup> measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CR<sub>MRD-</sub> ) without transplantation. Six of seven patients with molecular relapse/progression achieved CR<sub>MRD-</sub> after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1<sup>mut</sup> MRD.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2024-02-15T08:28:34.902Z","creation":"2022-02-09T15:50:50.736Z"},"accession":"S-EPMC8048658","cross_references":{"pubmed":["32458446"],"doi":["10.1111/bjh.16722"]}}